Abstract
Objective: to enhance the efficiency of intensive therapy and prevention of pyoseptic complications (PSC) of severe concomitant injury. Subjects and methods: A hundred patients who were divided into three groups were examined. A control group consisted of 30 apparently healthy individuals (donors). A study group comprised 38 patients to whom the standard of intensive care and prevention of PSC of severe concomitant injury was applied. A comparison group included 32 patients who received specific preventive therapy for pulmonary PSC, by incubating the cell mass with recombinant interleukin-2. Hemostatic parameters were followed up by biochemical tests and hemoviscosimetry. Immunological parameters, the data of semiquantitative procalcitonin test, and the clinical laboratory parameters of a systemic inflammatory response, as well as complications were analyzed. Results. In the intervention group, the signs of a systemic inflammatory response regressed beginning on day 2 of therapy, the results of the procalcitonin test and vascular thrombocytic hemostasis became normal and the time of respiratory support and the length of intensive care unit stay reduced. Conclusion. The early combination of cell mass with recombinant interleukin-2, beginning on day 2 of therapy for severe concomitant injury, enhances the efficiency of intensive therapy and prevention of pulmonary PSC. Key words: severe concomitant injury, infectious complications, diagnosis, recombinant interleukin-2.
Highlights
МУЗ «Городская клиническая больница No 3 им
Subjects and methods: A hundred patients who were divided into three groups were examined
The signs of a systemic inflammatory response regressed beginning on day 2 of therapy, the results of the procalcitonin test and vascular thrombocytic hemostasis became normal and the time of respiratory support and the length of intensive care unit stay reduced
Summary
МУЗ «Городская клиническая больница No 3 им. М. Цель исследования — повысить эффективность интенсивной терапии и профилактики гнойно септических осложне ний (ГСО) тяжелой сочетанной травмы. Основную группу (n=38) со ставили больные, которым проводили стандарт интенсивной терапии и профилактики гнойно септических осложне ний тяжелой сочетанной травмы. Раннее использование инку бации клеточной массы с рекомбинантным интерлейкином 2, начиная со вторых суток терапии тяжелой сочетанной травмы, позволяет повысить эффективность интенсивной терапии и профилактики легочных гнойно септических ос ложнений. A study group comprised 38 patients to whom the standard of intensive care and prevention of PSC of severe concomitant injury was applied. The early combination of cell mass with recombinant interleukin 2, beginning on day 2 of therapy for severe concomitant injury, enhances the efficiency of intensive therapy and prevention of pulmonary PSC. Эти ос ложнения могут быть местными (в области ранения и травмы), системными
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
